MediWound Ltd Q2 2025 Earnings Call Highlights: Revenue Growth Amid Rising Costs

MediWound Ltd reported a 43% sequential revenue growth in Q2 2025, driven by higher product sales and a favorable revenue mix. However, operating loss increased to $5.7 million, and net loss reached $13.3 million, driven by non-cash financial expenses. Research and development expenses rose to $3.5 million, and the cash position decreased to $32.9 million. The company is actively enrolling patients in the ScarX Value Phase 3 trial and expanding its Nexobrid product in the US market.

MediWound Ltd. (NASDAQ: MDWD) announced its Q2 2025 earnings results on Thursday, August 14th, before the market open. The company reported a 43% sequential revenue growth, driven by higher product sales and a favorable revenue mix. Total revenue for the quarter was $5.68 million, up 12.3% year-over-year (Y/Y) [1].

Despite the revenue growth, MediWound faced operational challenges. The company reported an operating loss of $5.7 million for Q2 2025, up 43% sequentially from Q1 2025 and higher year-over-year compared to Q2 2024. The net loss reached $13.3 million, or $1.23 per share, primarily due to non-cash financial expenses from warrant revaluation in Q2 2025 [2].

Research and development expenses rose to $3.5 million, up from $1.9 million in the prior year period, mainly driven by investment in the EscharEx VALUE Phase III study. SG&A expenses totaled $3.6 million, up from $3 million in the prior year period, primarily due to increased share-based compensation. The cash position decreased to $32.9 million as of June 30, 2025 [2].

MediWound is actively enrolling patients in the EscharEx VALUE Phase III trial for venous leg ulcers and expanding its NexoBrid product in the U.S. market. The company reported 52% year-over-year revenue growth for NexoBrid in Q2 2025, driven by higher hospital orders and additional ordering centers. The commissioning of the manufacturing facility remains on track for completion by year-end [2].

The company also announced new collaborations with ConvaTec and SCT to integrate category-leading wound care products into pivotal trials. A new post hoc analysis from the earlier Phase II study, published in Advances in Wound Care, reported wound bed preparation as a key predictor of healing, supporting EscharEx's clinical endpoint [2].

MediWound's earnings call highlighted the company's progress in its clinical and commercial objectives. The company is well-positioned to achieve key milestones over the next twelve months, which are expected to advance its strategic and financial objectives. However, the company's operational challenges, including increased operating and net losses, warrant close attention from investors.

References:
[1] https://seekingalpha.com/news/4484756-mediwound-q2-2025-earnings-preview
[2] https://www.fool.com/earnings/call-transcripts/2025/08/14/mediwound-mdwd-q2-2025-earnings-call-transcript/